“Why Is CVS Selling Party Packs of M&Ms Alongside Ozempic?” | Pashazadeh & Rees
A surgeon-turned-investment banker who still practices emergency medicine and the CEO developing mitochondria-targeted obesity drugs discuss GLP-1s — the $13 billion drug class reshaping healthcare — why appetite suppression comes with costs, and whether the next generation of obesity treatment can preserve muscle while losing fat.